Available Compounds
On this page
Available compounds
Diversity collection
Set |
384w plates |
Compounds |
---|---|---|
ChemBridge |
75 |
23,865 |
ChemDiv |
157 |
50,000 |
SPECS |
95 |
30,256 |
CB Premium |
157 |
50,000 |
Celera Combi Cluster |
12 |
3,840 |
Total |
157,961 |
Kinase-targeted collection
Set |
384w plates |
Compounds |
---|---|---|
ChemDiv |
32 |
10,000 |
I.F. Labs |
38 |
13,010 |
LifeChem |
4 |
970 |
CB Ion / Kinase |
101 |
32,000 |
Total |
55,980 |
Protease-targeted collection
Set |
384w plates |
Compounds |
---|---|---|
Celera |
6 |
1,817 |
LifeChem |
16 |
5,000 |
Total |
6,817 |
Drug collection
Set |
384w plates |
Compounds |
---|---|---|
Pharmakon |
5 |
1,600 |
SMDC Drugs |
2 |
577 |
Total |
2,177 |
Bioactive collection
Set |
384w plates |
Compounds |
---|---|---|
SelleckChem bioactive |
6x 12 serial dilutions |
1,835 |
SelleckChem epigenetic |
1 |
119 |
Total |
1,954 |
Carboxamide collection
Set |
384w plates |
Compounds |
---|---|---|
ChemDiv |
14 |
4,417 |
Fragment collection
Set |
MW range |
Selection/filtering criteria |
Compounds |
---|---|---|---|
Disulfide trapping |
–– |
Synthesized compounds for tethering/disulfide trapping technology |
1,300 |
Sigma-Aldrich | 84–286 | Drug-like functionality, solubility, contain acid or amine for optimization | 292 |
Maybridge RO3 |
94–300 |
Rule-of-Three compliance, solubility, purity |
995 |
Life Chemicals |
100–260 |
Aliphatic cycles, drug-like groups underrepresented in other |
1,456 |
Asinex |
123–269 |
Natural product-like molecules |
263 |
|
Total |
4,306 |
GSK
Set |
384w plates |
Compounds |
---|---|---|
PKIS Kinase |
2 |
330 |
Available compounds (some restrictions apply)
NCI (NIH funded / oncology requirement)
Set |
384w plates |
Compounds |
---|---|---|
Diversity |
277 |
87,522 |
Protease |
34 |
9,805 |
PPI |
21 |
6,044 |
Fragment |
9 |
2,706 |
Bioactive |
8 |
2,190 |
Natural Product |
6 |
872 |
Macrocycle |
1 |
291 |
Total |
109,430 |